🔬 Current Disease Focus:
Task Progress: 0%
👥 Active Problem Solvers
0
🌍 Experts collaborating globally
⚡ Current Task Assignment
🧬 Genetic Analysis
🔄 Matching experts to specific tasks
📊 Resource Allocation by Research Phase:
📚 Data Analysis
🧪 Experimental Design
🔬 Clinical Trials
💊 Treatment Development
The primary objectives of the study are to evaluate the safety of BIIB061 v...
Status
Withdrawn
Location
Multiple Locations
Start Date
2021-06-30
Trial ID
NCT04079088
Treatments Being Tested
The purpose of this study is to assess the effect of Diclofenac Sodium Topi...
Status
Completed
Location
MS Center at Evergreen Healthcare
Start Date
2011-01
Trial ID
NCT01454791
Treatments Being Tested
This open-label extension study will evaluate the long-term safety of glati...
Status
Completed
Location
Teva Investigational Site 009
Start Date
1994-03-26
Trial ID
NCT00203021
Treatments Being Tested
This study is designed to compare injection skin (injection site) reactions...
Status
Completed
Location
Multiple Locations
Start Date
2004-10
Trial ID
NCT00240032
To determine if treatment with BG00012 can decrease the number of MS relaps...
Status
Completed
Location
Research Site
Start Date
2007-06
Trial ID
NCT00451451
Treatments Being Tested
This study will investigate the efficacy, safety and tolerability of a new ...
Status
Terminated
Location
Teva Investigational Site 10192
Start Date
2012-03
Trial ID
NCT01578785
Treatments Being Tested
The purpose of this study is to determine if natalizumab in combination wit...
Status
Completed
Location
Multiple Locations
Start Date
2003-06
Trial ID
NCT00097760
Treatments Being Tested
Teva is developing 40 mg/ml Glatiramer Acetate (GA) Injection , administere...
Status
Completed
Location
Teva Benelux
Start Date
2006-07-27
Trial ID
NCT00326625
Treatments Being Tested
Participants with multiple sclerosis that are currently treated with glatir...
Status
Withdrawn
Location
Multiple Locations
Start Date
2010-02
Trial ID
NCT00988988
Treatments Being Tested
A multinational, multicenter, randomized, Phase III, double blind, parallel...
Status
Completed
Location
Mapi Pharma Research site 08
Start Date
2019-09-19
Trial ID
NCT04121221